The Second Circuit Court recently decided against Acorda Therapeutics Inc.’s attempt to enhance an arbitral award related to its multiple sclerosis drug, Ampyra. Acorda sought to augment its initial $16.6 million award by nearly $66 million, a request the court denied, noting the company had “slept on its rights” to modify the outcome. The court’s decision highlights the complexities in navigating post-award disputes in arbitration processes, especially in the pharmaceutical sector where significant financial stakes are often in play.
The litigation stems from Acorda’s royalty disagreements concerning Ampyra, a drug aimed at improving walking in patients with multiple sclerosis. The refusal to adjust the award underscores the judiciary’s reluctance to intervene in arbitral decisions once issued, especially when the parties involved did not timely assert their rights during the arbitration (Law360 report on the case, Law360).
Such legal nuances in arbitral award adjustments are not isolated. The pharmaceutical industry frequently encounters arbitration, often necessitating careful attention to contractual agreements and timelines. A similar case involved royalty disputes over Pfizer’s lupus drug, which illuminated the legal intricacies and the necessity of vigilance in protecting intellectual property rights and contractual interests (as discussed in detail by Reuters).
The outcome in Acorda’s case may have broader implications, signaling to legal practitioners and corporate entities the critical importance of diligently monitoring arbitration processes and ensuring proactive engagement in all procedural aspects to safeguard their interests effectively. As the legal landscape continues to evolve in this domain, entities must remain astute, understanding that the courts are increasingly advocating for finality and non-interference post-arbitration—a trend likely to persist in future legal interpretations.